medical device investing Helus Pharma Strengthens Executive Team with Appointment of Jill Conwell as Chief People Officer
medical device investing Helus Pharma Announces Topline Results in Phase 2 Signal Detection Study for HLP004 in Patients with Generalized Anxiety Disorder
medical device investing Helus Pharma Appoints Former Pfizer Chief Medical Officer Dr. Freda Lewis-Hall to Board of Directors & Chair of the Scientific Advisory Committee
medical device investing Nature Medicine Publishes Helus Pharma's Randomized, Placebo-Controlled Phase 2a Trial of SPL026 in Major Depressive Disorder
medical device investing Nature Medicine Publishes Helus Pharma's Randomized, Placebo-Controlled Phase 2a Trial of SPL026 in Major Depressive Disorder
medical device investing Nature Medicine Publishes Helus Pharma's Randomized, Placebo-Controlled Phase 2a Trial of SPL026 in Major Depressive Disorder
medical device investing Nature Medicine Publishes Helus Pharma's Randomized, Placebo-Controlled Phase 2a Trial of SPL026 in Major Depressive Disorder
medical device investing Nature Medicine Publishes Helus Pharma's Randomized, Placebo-Controlled Phase 2a Trial of SPL026 in Major Depressive Disorder
medical device investing HELUS Pharma Reports Third Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights
medical device investing HELUS Pharma Reports Third Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights
medical device investing HELUS Pharma Reports Third Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights
medical device investing Helus Pharma Appoints Michael Cola as Chief Executive Officer to Lead Next Phase of Scale and Execution
Oreterra Confirms Two Broad Zones of Epithermal Gold Mineralization with Assays to 50.5 g/t Au Overlying Porphyry Targets at the Kinkaid Project, Nevada
RUA GOLD Reports Extensions Along Strike and at Depth at the Auld Creek Gold-Antimony Project, Reefton Goldfield
